Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer : Preliminary analysis of the results of the IMPACT study

Mitra, Anita V. ; Bancroft, Elizabeth K. ; Barbachano, Yolanda ; Page, Elizabeth C. ; Foster, C. S. ; Jameson, C. ; Mitchell, G. ; Lindeman, G. J. ; Stapleton, A. and Suthers, G. , et al. (2011) In BJU International 107(1). p.28-39
Abstract

OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA >3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial... (More)

OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA >3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
keywords
BRCA1, BRCA2, genetic predisposition, prostate cancer, PSA
in
BJU International
volume
107
issue
1
pages
12 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:78650657873
  • pmid:20840664
ISSN
1464-4096
DOI
10.1111/j.1464-410X.2010.09648.x
language
English
LU publication?
no
id
2392d166-2e64-45d3-894b-e401fd42f88a
date added to LUP
2022-12-06 15:35:02
date last changed
2024-05-02 19:14:54
@article{2392d166-2e64-45d3-894b-e401fd42f88a,
  abstract     = {{<p>OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA &gt;3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.</p>}},
  author       = {{Mitra, Anita V. and Bancroft, Elizabeth K. and Barbachano, Yolanda and Page, Elizabeth C. and Foster, C. S. and Jameson, C. and Mitchell, G. and Lindeman, G. J. and Stapleton, A. and Suthers, G. and Evans, D. G. and Cruger, D. and Blanco, I. and Mercer, C. and Kirk, J. and Maehle, L. and Hodgson, S. and Walker, L. and Izatt, L. and Douglas, F. and Tucker, K. and Dorkins, H. and Clowes, V. and Male, A. and Donaldson, A. and Brewer, C. and Doherty, R. and Bulman, B. and Osther, P. J. and Salinas, M. and Eccles, D. and Axcrona, K. and Jobson, I. and Newcombe, B. and Cybulski, C. and Rubinstein, W. S. and Buys, S. and Townshend, S. and Friedman, E. and Domchek, S. and Ramon Y Cajal, T. and Spigelman, A. and Teo, S. H. and Nicolai, N. and Aaronson, N. and Ardern-Jones, A. and Bangma, C. and Dearnaley, D. and Eyfjord, J. and Falconer, A. and Hamdy, F. and Johannsson, O. and Khoo, V. and Kote-Jarai, Z. and Lilja, H. and Lubinski, J. and Melia, J. and Moynihan, C. and Peock, S. and Rennert, G. and Schröder, F. and Sibley, P. and Suri, M. and Wilson, P. and Bignon, Y. J. and Strom, S. and Tischkowitz, M. and Liljegren, A. and Ilencikova, D. and Abele, A. and Kyriacou, K. and Van Asperen, C. and Kiemeney, L. and Easton, D. F. and Eeles, Rosalind A.}},
  issn         = {{1464-4096}},
  keywords     = {{BRCA1; BRCA2; genetic predisposition; prostate cancer; PSA}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{28--39}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{BJU International}},
  title        = {{Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer : Preliminary analysis of the results of the IMPACT study}},
  url          = {{http://dx.doi.org/10.1111/j.1464-410X.2010.09648.x}},
  doi          = {{10.1111/j.1464-410X.2010.09648.x}},
  volume       = {{107}},
  year         = {{2011}},
}